Waldenström Macroglobulinemia
📧 Sign up to get email alerts when something new happens for Waldenström Macroglobulinemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-12-19Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia [Phase 4]
This Phase 4 study is recruiting to evaluate the efficacy and safety of zanubrutinib in treatment-naive Chinese adults with Waldenström macr…
-
CLINICAL_TRIALS research · 2025-12-10Clinical Trial Update: AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma [Phase 1]
An ongoing Phase 1 clinical trial update for AS-1763 in adults with previously treated B-cell malignancies, including chronic lymphocytic le…
-
CLINICAL_TRIALS trial_result · 2025-12-05Clinical Trial Update: Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial update evaluating the efficacy of the first-line B-RI regimen in treatment-naive Waldenström's macroglobulinemia.
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia [Phase 2]
Phase 2 study evaluating safety and efficacy of pacritinib in relapsed or refractory Waldenström macroglobulinemia; the trial is currently r…
-
CLINICAL_TRIALS research · 2025-12-05Clinical Trial Update: ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy [Phase 2]
Phase 2 clinical trial update for ACALA-R in predominantly demyelinating IgM-mediated neuropathy; the study involves IgM monoclonal gammopat…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-12-04Clinical Trial Update: Innovative Biomarkers of Cardiovascular Complications Associated With Second-generation Bruton Tyrosine Kinase Inhibitor Treatments: a Single-center Cohort Study
A single-center cohort study is assessing biomarkers of cardiovascular complications in patients treated with second-generation BTK inhibito…
-
CLINICAL_TRIALS trial_result · 2025-12-02Clinical Trial Update: Multicenter, Single-Arm Exploratory Phase I Clinical Study (Assessment of Safety and Efficacy) of Fully Human BAFF-R Chimeric Antigen Receptor T-Cell Injection in Relapsed/Refractory BAFF-R-Positive B-Cell Lymphoma [Phase 1, Phase 2]
Clinical trial update describing a multicenter, single-arm Phase I/II exploratory study to assess the safety and efficacy of a fully human B…
-
CLINICAL_TRIALS research · 2025-12-02Clinical Trial Update: A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia [Phase 2]
This clinical trial update describes a Phase II study evaluating zanubrutinib in combination with four cycles of a CD20 monoclonal antibody …
-
CLINICAL_TRIALS research · 2025-11-28Clinical Trial Update: Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy of venetoclax in combination with rituximab for Waldenström macroglobulinemia. The study…
-
CLINICAL_TRIALS trial_result · 2025-11-26Clinical Trial Update: Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Completed clinical trial update examining how patients with multiple myeloma and Waldenström macroglobulinemia respond to COVID-19 vaccinati…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Study Evaluating the Efficacy and Tolerance of a Zanubrutinib and BGB-11417 Combination in Patients Previously Treated for Waldenström Macroglobulinemia [Phase 2]
Phase 2 clinical trial evaluating the combination of zanubrutinib and BGB-11417 in patients previously treated for Waldenström macroglobulin…
-
CLINICAL_TRIALS research · 2025-11-26Clinical Trial Update: Prognostic Analyses on a Validation Series of Patients With Waldenström's Disease
This clinical trial update describes planned prognostic analyses on a validation series of Waldenström macroglobulinemia patients and notes …
-
EMA approval · 2025-11-24EMA Authorised: Brukinsa (zanubrutinib) — BeOne Medicines Ireland Limited
The European Medicines Agency authorised Brukinsa (zanubrutinib) for Waldenström macroglobulinemia, with BeOne Medicines Ireland Limited as …
-
CLINICAL_TRIALS research · 2025-11-21Clinical Trial Update: Watch and Wait or Worry and Wait in Indolent Lymphoma
An ongoing clinical trial at Seoul National University Hospital is evaluating watchful waiting versus proactive worry-and-wait strategies in…
-
CLINICAL_TRIALS trial_result · 2025-11-18Clinical Trial Update: Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
The study evaluating non-invasive diagnostics and monitoring of minimal residual disease and clonal evolution in Waldenström macroglobulinem…
-
CLINICAL_TRIALS research · 2025-11-17Clinical Trial Update: A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) [Phase 2]
A Phase 2 clinical trial evaluating a triplet regimen of pirtobrutinib, venetoclax, and rituximab in Waldenström macroglobulinemia and lymph…
-
FDA approval · 2025-10-21FDA Approved: IMBRUVICA — Supplemental Application (Pharmacyclics LLC)
FDA approved a supplemental application for IMBRUVICA (ibrutinib) submitted by Pharmacyclics LLC.
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Q702 for the Treatment of Patients With Hematologic Malignancies [Phase 1]
This entry notes a Phase 1 clinical trial (Q702) for hematologic malignancies led by Mayo Clinic, currently recruiting and including histioc…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma [Phase 1]
This update outlines a Phase 1 study of genetically modified T-cell infusions following peripheral blood stem cell transplant for patients w…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]
Clinical trial update describes an ongoing Phase 1/2 study of selinexor in combination chemotherapy for advanced B-cell non-Hodgkin lymphoma…
-
CLINICAL_TRIALS research · 2025-09-29Clinical Trial Update: Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma [Phase 1, Phase 2]
Phase 1/2 clinical trial update evaluating the combination of nivolumab and lenalidomide in relapsed or refractory lymphomas (non-Hodgkin an…
-
CLINICAL_TRIALS research · 2025-09-23Clinical Trial Update: Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
This clinical trial update reports that recruitment is ongoing for a study evaluating zanubrutinib in patients with Waldenström's macroglobu…
-
CLINICAL_TRIALS trial_result · 2025-09-18Clinical Trial Update: Ibrutinib and Ixazomib Citrate in Treating Newly Diagnosed, Relapsed or Refractory Waldenstrom Macroglobulinemia [Phase 2]
Phase 2 study evaluating a combination of ibrutinib and ixazomib citrate in newly diagnosed, relapsed, or refractory Waldenström macroglobul…
-
CLINICAL_TRIALS research · 2025-09-11Clinical Trial Update: Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia [Phase 1]
Clinical trial update: A Phase 1 study is evaluating time-limited therapy with ibrutinib followed by bendamustine and rituximab in Waldenstr…
-
CLINICAL_TRIALS trial_result · 2025-09-10Clinical Trial Update: BR101801 in Adult Patients With Advanced Hematologic Malignancies(Phase I) [Phase 1]
Phase I clinical trial update for BR101801 in adults with advanced hematologic malignancies; the study has completed.